Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 97 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Results available

Inositol and Omega-3 Fatty Acids in Pediatric Mania

NCT01396486
Conditions
Pediatric Bipolar Spectrum Disorders
Interventions
Omega-3, Inositol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 12 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cystic Fibrosis
Interventions
RELiZORB (immobilized lipase) cartridge, Impact Peptide 1.5
Device · Other
Lead sponsor
Alcresta Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults

NCT03043365
Conditions
Lipoprotein Metabolism, PCSK9, Proteomics
Interventions
control fish oil, LCMUFA-rich saury oil
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions
ADHD Medication, Omega-3 Fatty Acids
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Conditions
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Interventions
Tart Cherry, Omega 3 FA (Fish Oil)
Drug
Lead sponsor
Philip Chang
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Torrance, California
Conditions
Depressive Disorder, Major
Interventions
Omega 3 Fatty Acids, Corn oil
Drug · Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 19 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Results available

SGA-induced Metabolic Syndrome in Bipolar Youth

NCT01858948
Conditions
Bipolar Youth Treated With Second-generation Antipsychotics
Interventions
Omega, Placebo, Quetiapine fumarate
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals

NCT05763940
Conditions
Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
Interventions
OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
Dietary Supplement
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pomona, California
Recruiting Not applicable Interventional Accepts healthy volunteers

Omega-3 Fatty Acids and Subconcussive Head Impacts

NCT06736925
Conditions
Subconcussive Head Impact, Omega-3 Fatty Acids
Interventions
Omega-3 Fatty Acids (EPA plus DHA), Organic soybean oil, Soccer Heading Model
Dietary Supplement · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bloomington, Indiana
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Omega-3 Fatty Acids and Insulin Sensitivity

NCT01686568
Conditions
Insulin Resistance
Interventions
Omega-3, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Therapeutic Omegas for Triglyceride Suppression

NCT04349475
Conditions
Pregnancy
Interventions
Intervention Omega 3 Supplementation, Placebo Soybean Oil
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma
Completed Not applicable Interventional Accepts healthy volunteers

Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women

NCT02101970
Conditions
Breast Cancer
Interventions
Omega-3 Fatty Acids, Placebo Capsule, Diet and Exercise
Dietary Supplement · Other
Lead sponsor
Carol Fabian, MD
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Fatty Liver
Interventions
Polyunsaturated fatty acid (Opti-EPA), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Pharmacodynamics of EPA and DHA From Fortified Soymilk and Capsules

NCT05802797
Conditions
Healthy Diet
Interventions
Algae Oil Fortified Soymilk, Algae Oil Capsule
Other · Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Autism
Interventions
Omega 3 fatty acids, Placebo
Drug · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Piscataway, New Jersey
Conditions
Stage 0 Breast Carcinoma, Breast Neoplasms, Stage I Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma
Interventions
Metformin, Omega-3 fatty acids
Drug
Lead sponsor
Katherine D. Crew
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Brain Trauma
Interventions
Plasma Neurofilament Light (NF-L), Omega-3 Index, HeadCount Questionnaire
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Kansas City, Missouri
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers

NCT00682318
Conditions
Healthy
Interventions
Fish Oil, Safflower Oil, Ethanol, Omega-3 polyunsaturated fatty acids, Omega-6 polyunsaturated fatty acid
Drug · Dietary Supplement
Lead sponsor
Carsten Skarke, MD
Other
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers

AlmegaPL CV Health Open Label Study

NCT05267301
Conditions
Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid
Interventions
AlmegaPL (FDA NDIN # 826)
Dietary Supplement
Lead sponsor
Qualitas Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Tempe, Arizona • Houston, Texas
Completed Phase 2 Interventional Results available

Fatty Acid Supplementation in Children With ASD

NCT03550209
Conditions
Autism Spectrum Disorder
Interventions
LCPUFA Oil Supplement, Canola Oil Placebo
Drug · Dietary Supplement
Lead sponsor
Sarah Keim
Other
Eligibility
2 Years to 6 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 1 Interventional Results available

NAPLS Omega-3 Fatty Acid Versus Placebo Study

NCT01429454
Conditions
Psychosis
Interventions
Omega-3 Long Chain Fatty Acid, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
12 Years to 30 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 5 more
Conditions
Suicide
Interventions
Study Juice, Placebo Juice
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina